Kaye Biotech Inc. had the following equity account balances at December 31, 2016: Preferred shares, $2.70, non-cumulative, Authorized: 21,000 shares Issued and outstanding: 5,500 shares $ 38,500 Common shares, Authorized: Unlimited Issued and outstanding: 87,500 shares 296,157 Retained earnings 42,600 On February 1, 2017, 5,500 preferred shares were issued at $8.20 each. The board of directors declared and paid the annual cash dividend on the preferred shares on June 30, 2017, and a 14% common share dividend was declared and distributed on the same day when the market price per common share was $4.45. On October 1, 2017, 21,000 common shares were issued at $4.59 each. Profit earned during 2017 was $413,800. Required: Using the information provided, prepare the statement of changes in equity for the year ended December 31, 2017. (Amounts to be deducted should be indicated by a minus sign.)